NEW YORK (GenomeWeb News) – Invitrogen said today that it has acquired VisiGen Biotechnologies, a developer of real-time single-molecule sequencing technology, for $20 million.
 
Invitrogen disclosed the purchase as part of its third-quarter financial report, in which it recorded a 15 percent increase in revenues to $362 million from $315 million in the third quarter of 2007.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: Icelandic genome sequences, approach to increase CRISPR efficiency, and more.

Testing showing "genetic incompatibilities" have led thousands of couples in Saudi Arabia to call off their weddings, the BBC reports.

Decode Genetics' ability to tell Icelanders, even ones the company hasn't sequenced, about their disease risk brings up ethical questions.

Genetic analysis of Britain's King Richard III and modern descendants of his relatives indicate breaks in the male line.

Apr
15
Sponsored by
WaferGen

This live online seminar will highlight recent trends in applying next-generation sequencing in the clinical setting, with a particular focus on oncology and rare disease.